Today: 10 June 2026
Browse Category

NASDAQ:SUPN 25 February 2026

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 25.02.2026

Supernus Pharmaceuticals reported Q4 earnings of $0.92 per share, beating the Zacks estimate of $0.28. Revenue rose to $211.57 million from $174.16 million a year earlier. The company has topped consensus estimates for four straight quarters. Shares are up 2% year-to-date, but the stock holds a Zacks Rank #5 (Strong Sell) due to negative earnings estimate revisions.
25 February 2026
·

Stock Market Today

  • Should You Buy Shares in SpaceX and Anthropic? A UK Investing Guide
    June 10, 2026, 10:15 AM EDT. Elon Musk's SpaceX is gearing up for what could be the largest initial public offering (IPO) ever, drawing significant investor attention. Alongside SpaceX, AI startup Anthropic is also on the radar for potential listings. This guide examines how UK investors can access shares in these tech giants, the risks involved, and whether these opportunities align with investor goals. With SpaceX's ambitious space ventures and Anthropic's AI focus, both companies represent cutting-edge technology sectors. However, potential investors should weigh the volatility and long-term outlook before committing funds. Understanding IPO mechanics and market conditions is crucial for making informed decisions.

Latest articles

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

Rigetti Computing Stock Falls as Sale Notice Tests $100 Million Quantum Rally

10 June 2026
Rigetti Computing plunged 9.55% to $19.69 Tuesday and dipped further premarket after director Ray O. Johnson filed to sell 122,188 shares worth $2.6 million, testing investor confidence following a recent rally on news of a potential $100 million U.S. Commerce Department quantum-computing award, with traders watching for binding funding terms amid ongoing volatility.
PATH slips again, investors keep questioning AI automation bet

PATH slips again, investors keep questioning AI automation bet

10 June 2026
UiPath shares slid 3.76% to $10.75 and dropped another 1.49% pre-market as investors focused on slowing annual recurring revenue growth—up 12% to $1.901 billion versus 17% revenue growth—raising doubts about AI automation’s impact on recurring sales; second-quarter ARR guidance of $1.929–$1.934 billion is now the key number for PATH’s stock direction.
Go toTop